Bionomics (BNOX) Stock Price, News & Analysis

Company Overview

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.

Key Stats

• Today's Range: $0.24 to $0.29
• 50-Day Range: $0.24 to $0.32
• 52-Week Range: $0.18 to $0.94
• Volume: 7.43 million shs
• Average Volume: 5.97 million shs
• Market Capitalization: $4.47 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.00
• Consensus Rating: Buy

BNOX Stock Analysis - Frequently Asked Questions

When did Bionomics IPO?

Bionomics (BNOX) raised $20 million in an IPO on Thursday, December 16th 2021. The company issued 1,622,000 shares at a price of $12.35 per share.

What other stocks do shareholders of Bionomics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bionomics investors own include Meta Platforms (META), PayPal (PYPL), Intel (INTC), ChargePoint (CHPT), CRISPR Therapeutics (CRSP) and NVIDIA (NVDA).

Company Calendar

• Today: 7/18/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BNOX
• CIK: 1191070
• Web: www.bionomics.com.au
• Phone: 088-150-7400
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Bionomics: $8.00
• High Price Target: $8.00
• Low Price Target: $8.00
• Potential Upside/Downside: +3,060.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.30
• Quick Ratio: 3.30

Sales & Book Value

• Annual Sales: $10 thousand
• Price / Sales: 446.82
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.32 per share
• Price / Book: 0.19

Miscellaneous

• Outstanding Shares: 17,654,000
• Free Float: 17,532,000
• Market Cap: $4.47 million
• Optionable: Not Optionable
• Beta: 0.26